Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has demonstrated significant operating margin expansion, which is projected to exceed 16%, up from an earlier estimate of 13%. The company is anticipated to achieve impressive year-over-year growth in organ transplant volumes, with estimates indicating a 35.2% increase and sales growth of approximately 40.5% in Q4 2025, surpassing consensus estimates. Additionally, positive trends such as higher adoption rates of the Organ Care System and robust international growth rates are expected to further enhance the company’s financial outlook.

Bears say

TransMedics Group Inc. has faced challenges in Q3, as evidenced by sequential declines in aviation metrics, specifically daily flights and flight hours, which resemble early-year levels. Despite reporting product revenue growth of 33.1% year-over-year, it fell short of consensus estimates by approximately $1 million, and with a gross margin of 58.8% missing expectations, doubts surrounding effective salesforce scaling and market penetration have arisen. Additionally, concerns about potential regulatory risks, competition, and reimbursement changes could hinder the company’s future growth and overall market performance.

TMDX has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 8 analysts, TMDX has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $144.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $144.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.